InflaRx shares soared 80% premarket after its experimental drug INF904 showed positive mid-stage trial results in treating Hidradenitis Suppurativa and Chronic Spontaneous Urticaria. The study demonstrated reduced disease severity and pain, supporting further development. The drug also showed a favorable safety and pharmacokinetics profile, the company said.